Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

IF 3 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2025-06-14 DOI:10.1007/s00277-025-06449-0

Jens Panse, Bing Han, Jaroslav Cermak, Fernando Ataulfo Gonzalez Fernandez, Akihiko Gotoh, Austin G Kulasekararaj, Olena Kyselova, Fahri Sahin, Phillip Scheinberg, Hubert Schrezenmeier, Nicole Straetmans, Yasutaka Ueda, Alice C Chang, Brittany Gentile, Jennifer Stefani, Marianne Uguen, Alexander Röth

引用次数: 0

查看原文本刊更多论文

在III期COMMODORE 2和1研究中，克罗伐单抗和批准的C5抑制剂治疗突发性夜间血红蛋白尿患者的患者报告结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.